Clinical Trial Update: A Phase 1 Study of ARN-6039 [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial of ARN-6039 in multiple sclerosis sponsored by Arrien Pharmaceuticals has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• ARN-6039

Snippet

Sponsor: Arrien Pharmaceuticals | Conditions: Multiple Sclerosis | Phase 1 | Status: COMPLETED